Although previous studies had noted that breast cancers arising in PALB2 mutation carriers were more likely to be ER-/PR-/HER2- (triple negative) [61,63-65], the triple-negative receptor status was not observed in our study. The gene discussed is ESR1; the disease is breast cancer.